SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from PTC THERAPEUTICS, INC. (PTCT) (CIK 0001070081) (PTCT) — Jan 13, 2016

PTC THERAPEUTICS, INC. (PTCT) (CIK 0001070081)
Date: Jan. 13, 2016 · CIK: 0001070081 · Accession: 0001104659-16-089681

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 001-35969

Referenced dates: December 15, 2015

Date
January 13, 2016
Author
/s/ Shane Kovacs
Form
CORRESP
Company
PTC THERAPEUTICS, INC. (PTCT) (CIK 0001070081)

Letter

Re:

January 13, 2016

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, NE

Mail Stop 4720

Washington, D.C. 20549

Attention: Jim B. Rosenberg

PTC Therapeutics, Inc.

Form 10-K for the Fiscal Year Ended December 31, 2014

Filed March 2, 2015

Form 10-Q for the Quarterly Period Ended September 30, 2015

Filed November 9, 2015

File No. 001-35969

Ladies and Gentlemen:

PTC Therapeutics, Inc. (the “Company”) confirms that it is in receipt of a comment letter (the “Comment Letter”) from the Staff (the “Staff”) of the Securities and Exchange Commission, dated December 15, 2015, regarding the above-referenced filings of the Company. The Company is working diligently to complete its response to the Staff, but due to logistical issues, including the end of the holiday season and management team travel schedules, requires additional time to finalize its response. On January 13, 2016, a representative of the Company spoke with the Staff and the Staff agreed to provide an additional one week extension for the Company’s response. The Company appreciates the Staff’s willingness to allow for the additional time and the Company will provide its response on or before January 21, 2016.

Please call the undersigned at (908) 912-9466 if you have any questions regarding this letter.

Very truly yours,
/s/ Shane Kovacs

Show Raw Text
CORRESP
1
filename1.htm

January 13, 2016

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, NE

Mail Stop 4720

Washington, D.C. 20549

Attention: Jim B. Rosenberg

Re:

PTC   Therapeutics, Inc.

Form 10-K   for the Fiscal Year Ended December 31, 2014

Filed   March 2, 2015

Form 10-Q   for the Quarterly Period Ended September 30, 2015

Filed   November 9, 2015

File   No. 001-35969

Ladies and Gentlemen:

PTC Therapeutics, Inc. (the “Company”) confirms that it is in receipt of a comment letter (the “Comment Letter”) from the Staff (the “Staff”) of the Securities and Exchange Commission, dated December 15, 2015, regarding the above-referenced filings of the Company. The Company is working diligently to complete its response to the Staff, but due to logistical issues, including the end of the holiday season and management team travel schedules, requires additional time to finalize its response. On January 13, 2016, a representative of the Company spoke with the Staff and the Staff agreed to provide an additional one week extension for the Company’s response. The Company appreciates the Staff’s willingness to allow for the additional time and the Company will provide its response on or before January 21, 2016.

Please call the undersigned at (908) 912-9466 if you have any questions regarding this letter.

Very truly yours,

/s/ Shane Kovacs

Shane Kovacs

Chief Financial Officer